Blog - Adult Onset Vitelliform Dystrophy
A 41 year old male patient came with history of diminished vision in both eyes since 5 months. His best corrected visual acuity was 6/6 in both eyes with glasses. Fundus evaluation showed subretinal fluid at macula with subretinal fibrin deposition inferior to fovea.
![](https://www.primeretina.com/wp-content/uploads/2023/06/Blog-Prime-Retina-002-1024x421.png)
![](https://www.primeretina.com/wp-content/uploads/2023/06/Blog-Prime-Retina-003-1024x436.png)
OCT : shows a hyperreflective material between neurosensory retina and RPE
![](https://www.primeretina.com/wp-content/uploads/2023/06/Blog-Prime-Retina-004.jpg)
![](https://www.primeretina.com/wp-content/uploads/2023/06/Blog-Prime-Retina-005.jpg)
ADULT ONSET VITELLIFORM MACULAR DYSTROPHY(AVMD)
Clinical Manifestations
Classically, AVMD changes include
- Sporadic, although some familial clustering has been reported,
- Onset typically between 30-50 years of age,
- Autofluorescent, subfoveal yellow vitelliform-like lesion 500-700µm in size,
- No visual symptoms, or-mild-moderate visual acuity decrease,
- Hyperreflective material between the NSR and the RPE.
Complications of AVMD include:
Choroidal neovascularization,
RPE detachment
TREATMENT:
At present, no definitive therapies or treatments exist for patients with bestrophinopathies.
- Gene therapies
- Stem cell based retinal pigment epithelium transplantation
Both the therapies are under intense research